Abstract
Adrenergic mechanisms are involved in the formation of several types of pulmonary edema (PE) such as neurogenic pulmonary edema (NPE) or PE in patients with pheochromocytoma, but also in the development of pulmonary fibrosis and pulmonary hypertension. In severe cases of PE such as in the adult respiratory distress syndrome (ARDS), PE is typically accompanied by inflammation and followed by pulmonary vascular hypertrophy and pulmonary fibrosis. Norepinephrine and other adrenoceptor agonists are known to provoke activation of proinflammatory cytokines such as interleukin (IL)-1 and IL-6. These cytokines are involved both in the pathogenesis of PE and of pulmonary fibrosis. We therefore assume that adrenergic mechanisms may have an important role in the pathogenesis of pulmonary injuries characterized by edema, inflammation and fibrosis. The contribution of adrenoceptor stimulation, particularly the distinct role of α- and β-adrenergic mechanisms, to the development of PE and pulmonary fibrosis is reviewed in this paper.
Keywords: Acute lung injury, adrenergic agonists, adrenergic antagonists, isoproterenol, norepinephrine, pulmonary edema, pulmonary inflammation, pulmonary fibrosis, phenylephrine, sympathetic stimulation.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis
Volume: 13 Issue: 3
Author(s): Beate Rassler
Affiliation:
Keywords: Acute lung injury, adrenergic agonists, adrenergic antagonists, isoproterenol, norepinephrine, pulmonary edema, pulmonary inflammation, pulmonary fibrosis, phenylephrine, sympathetic stimulation.
Abstract: Adrenergic mechanisms are involved in the formation of several types of pulmonary edema (PE) such as neurogenic pulmonary edema (NPE) or PE in patients with pheochromocytoma, but also in the development of pulmonary fibrosis and pulmonary hypertension. In severe cases of PE such as in the adult respiratory distress syndrome (ARDS), PE is typically accompanied by inflammation and followed by pulmonary vascular hypertrophy and pulmonary fibrosis. Norepinephrine and other adrenoceptor agonists are known to provoke activation of proinflammatory cytokines such as interleukin (IL)-1 and IL-6. These cytokines are involved both in the pathogenesis of PE and of pulmonary fibrosis. We therefore assume that adrenergic mechanisms may have an important role in the pathogenesis of pulmonary injuries characterized by edema, inflammation and fibrosis. The contribution of adrenoceptor stimulation, particularly the distinct role of α- and β-adrenergic mechanisms, to the development of PE and pulmonary fibrosis is reviewed in this paper.
Export Options
About this article
Cite this article as:
Rassler Beate, Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/1871529X1303140129154602
DOI https://dx.doi.org/10.2174/1871529X1303140129154602 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic and Environmental Determinants of Early Vascular Ageing (EVA)
Current Vascular Pharmacology Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Role of Hyperphosphatemia on Cardiovascular Disease in Dialysis Patients
Vascular Disease Prevention (Discontinued) Ultrasonic-Promoted One-Pot Synthesis of 4H-chromenes, pyrano[2,3- d]pyrimidines, and 4H-pyrano[2,3-c]pyrazoles
Letters in Organic Chemistry Alpinia calcarata Roscoe: A Rich Source of Phytopharmaceuticals in Sri Lanka
The Natural Products Journal Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews Hypoxia and Oxidative Stress in the Causation of Diabetic Retinopathy
Current Diabetes Reviews The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema
Cardiovascular & Hematological Disorders-Drug Targets Histological Alterations in the Testicular Tissue Induced by Sildenafil Overdoses
Drug Metabolism Letters Obstructive Sleep Apnea as an Independent Stroke Risk Factor: Possible Mechanisms
Current Molecular Medicine Preparation and Evaluation of ‘3 Cap’ Pulsatile Drug Delivery System of Ramipril
Cardiovascular & Hematological Agents in Medicinal Chemistry The Effects of Interleukin-10 on the Expression of Fas and FasL in Rat Hepatic Stellate Cells
Medicinal Chemistry The Role of P-glycoprotein in Cerebral Amyloid Angiopathy; Implications for the Early Pathogenesis of Alzheimers Disease
Current Alzheimer Research The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise
Current Molecular Medicine Molecular Markers of Cardiovascular Damage in Hypertension
Current Pharmaceutical Design Editorial [Hot topic: Anti-Angiogenic Agents (Executive Editor: Maurizio Botta and Anna Di Donna)]
Current Pharmaceutical Design High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery MiR-106a Associated with Diabetic Peripheral Neuropathy Through the Regulation of 12/15-LOX-meidiated Oxidative/Nitrative Stress
Current Neurovascular Research Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases
Current Pharmaceutical Design